Floatz logo

Alvespimycin

Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

53 Active assets in the Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BBB
DEXAMETHASONE
Mingzhi Zhang
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Centre, Singapore
Phase 4BBB
Tucidinostat
Ruijin Hospital
Phase 4BB
ETOPOSIDE
Tarapeutics Science Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

Alvespimycin is also rated in:

cancer of unknown primary siteDormant
CCC
Indicative ·
52 / 100
View asset →
salivary gland adenoid cystic carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Stage IV Adult Diffuse Small Cleaved Cell LymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →